File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B

TitlePrevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
Authors
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2003, v. 36 n. 6, p. 687-696 How to Cite?
AbstractYMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median serum HBV DNA concentration at 1 year was <20% of the baseline level, and serum alanine transaminase (ALT) levels and liver histologic findings had significantly improved. In patients with YMDD variants who were treated for up to 4 years, median HBV DNA and ALT levels showed improvements. Sex, baseline body mass index, and HBV DNA level were associated with emergence of YMDD variants. Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy.
Persistent Identifierhttp://hdl.handle.net/10722/42155
ISSN
2015 Impact Factor: 8.736
2015 SCImago Journal Rankings: 4.742
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_HK
dc.contributor.authorDienstag, Jen_HK
dc.contributor.authorSchiff, Een_HK
dc.contributor.authorLeung, NWYen_HK
dc.contributor.authorAtkins, Men_HK
dc.contributor.authorHunt, Cen_HK
dc.contributor.authorBrown, Nen_HK
dc.contributor.authorWoessner, Men_HK
dc.contributor.authorBoehme, Ren_HK
dc.contributor.authorCondreay, Len_HK
dc.date.accessioned2007-01-08T02:30:25Z-
dc.date.available2007-01-08T02:30:25Z-
dc.date.issued2003en_HK
dc.identifier.citationClinical Infectious Diseases, 2003, v. 36 n. 6, p. 687-696en_HK
dc.identifier.issn1058-4838en_HK
dc.identifier.urihttp://hdl.handle.net/10722/42155-
dc.description.abstractYMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median serum HBV DNA concentration at 1 year was <20% of the baseline level, and serum alanine transaminase (ALT) levels and liver histologic findings had significantly improved. In patients with YMDD variants who were treated for up to 4 years, median HBV DNA and ALT levels showed improvements. Sex, baseline body mass index, and HBV DNA level were associated with emergence of YMDD variants. Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy.en_HK
dc.format.extent198945 bytes-
dc.format.extent3035 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/en_HK
dc.relation.ispartofClinical Infectious Diseasesen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsClinical Infectious Diseases. Copyright © University of Chicago Press.en_HK
dc.subject.meshAntiviral agents - adverse effects - therapeutic useen_HK
dc.subject.meshDna, viral - blooden_HK
dc.subject.meshHepatitis b virus - drug effects - genetics - immunologyen_HK
dc.subject.meshLamivudine - adverse effects - therapeutic useen_HK
dc.subject.meshAlanine transaminase - blooden_HK
dc.titlePrevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1058-4838&volume=36&issue=6&spage=687&epage=696&date=2003&atitle=Prevalence+and+Clinical+Correlates+of+YMDD+Variants+during+Lamivudine+Therapy+for+Patients+with+Chronic+Hepatitis+Ben_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1086/368083en_HK
dc.identifier.pmid12627352-
dc.identifier.scopuseid_2-s2.0-0037443950en_HK
dc.identifier.hkuros80555-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037443950&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue6en_HK
dc.identifier.spage687en_HK
dc.identifier.epage696en_HK
dc.identifier.isiWOS:000181451200003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridDienstag, J=24498972800en_HK
dc.identifier.scopusauthoridSchiff, E=7102846957en_HK
dc.identifier.scopusauthoridLeung, NWY=26643107200en_HK
dc.identifier.scopusauthoridAtkins, M=16738020300en_HK
dc.identifier.scopusauthoridHunt, C=7201450839en_HK
dc.identifier.scopusauthoridBrown, N=7403548663en_HK
dc.identifier.scopusauthoridWoessner, M=6603331867en_HK
dc.identifier.scopusauthoridBoehme, R=8094923900en_HK
dc.identifier.scopusauthoridCondreay, L=7004527800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats